Fig. 2.

NME2-mediated MYC transcription is inhibited by stauprimide in cancer cells. (A) qRT-PCR analysis of NME2 and MYC mRNA levels in RXF 393 and CAKI-1 renal cancer cells following transfection of NME2 targeting siRNAs in the cells. (B) Western blotting of indicated proteins for nuclear and cytosolic fractions of RXF 393 and CAKI-1 cell lysates upon stauprimide treatment (5 μM) for 3 h. (C) qRT-PCR for MYC mRNA in indicated cell lines treated with stauprimide for 6 h in dose–response format.